On Thursday, Goldman Sachs (NYSE:GS) initiated coverage on shares of Intuitive Surgical (NASDAQ:ISRG) with a Buy rating and a price target of $500.00. The firm's outlook on the stock is positive, citing several factors that could contribute to the company's growth.
The coverage is based on the potential for increased penetration of robotic-assisted surgery (RAS), which could be accelerated by advancements in next-generation products. Intuitive Surgical is also in the initial phase of developing a fully-integrated care delivery model that encompasses intervention, data analytics, and the prospect of eventually automating surgery.
Goldman Sachs further predicts that Intuitive Surgical's profit and loss statement will exhibit positive momentum starting in 2026, following a period of lower gross margins expected next year. The firm projects approximately 20% growth in earnings per share (EPS) through 2028.
The analyst's statement emphasizes the company's strong position in the market and its potential for continued innovation and expansion in the field of robotic-assisted surgery. Intuitive Surgical's focus on integrating various aspects of care delivery is expected to contribute to its long-term financial performance and market presence.
The price target of $500.00 reflects Goldman Sachs' confidence in Intuitive Surgical's strategy and the anticipated positive financial developments over the coming years. As the company progresses through its forecasted trough in gross margins, the firm anticipates a significant growth trajectory for earnings per share.
InvestingPro Insights
Goldman Sachs' optimistic coverage on Intuitive Surgical aligns with some of the real-time metrics from InvestingPro. The company's Market Cap stands robust at $141.31B, and its Revenue Growth over the last twelve months as of Q1 2024 is a healthy 13.81%. This demonstrates Intuitive Surgical's solid financial performance in the recent period, supporting the potential for increased market penetration highlighted by Goldman Sachs.
InvestingPro Tips further suggest that Intuitive Surgical is trading at a high earnings multiple, with a P/E Ratio of 70.41, and a high Price / Book multiple of 10.12 as of Q1 2024. These metrics indicate that the market has high expectations for the company's future earnings. Additionally, the company's stock has experienced a large price uptick over the last six months, with a 28.17% return, nearing its 52-week high at 97.54% of the peak price. Intuitive Surgical's financial stability is underpinned by the fact that its liquid assets exceed short-term obligations, which is a positive sign for investors considering the firm's potential for continued innovation in robotic-assisted surgery.
For readers looking to delve deeper into Intuitive Surgical's financial health and future prospects, InvestingPro offers a wealth of additional insights. There are currently over 15 additional InvestingPro Tips available, which can be accessed with an exclusive discount. Use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.